KPTI Karyopharm Therapeutics Inc.
USHealthcareAs of 2026-07-10 16:00
Why KPTI matters now
Karyopharm Therapeutics Inc. (KPTI) is a US stock in Healthcare. The latest InvestLog snapshot shows $10.34 with +1.37% on the session and $234.3M in market capitalization; recent performance reads 1-month +20.75% and YTD +22.55%.
The latest financial table shown here is Q1 2026, with revenue of $35.1M, net income of $-22.4M, and EPS of $-1.24. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -28.9%.
The latest indexable market news headline is "Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $16.00; recent insider activity includes Greene Barry E filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-0.75
P/S
1.35
EV/EBITDA
-2.33
DCF Value
$-77.29
FCF Yield
-28.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
96.0%
Operating Margin
-55.7%
Net Margin
-129.0%
ROE
73.1%
ROA
-148.4%
ROIC
-177.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $35.1M | $-22.4M | $-1.24 |
| Q4 2025 | $34.1M | $-102.2M | $-5.69 |
| FY 2025 | $146.1M | $-196.0M | $-17.93 |
| Q3 2025 | $44.0M | $-33.1M | $-3.82 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$19.00
Target (Median)
$16.00
Target Range
$13.00 - $28.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.82
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.